Is there a place for interferon alpha in treatment strategy of multicentric Castleman's disease?;Y a-t-il une place pour l'interferon-α dans la strategie therapeutique de la maladie de Castleman multicentrique?

Revue de Medecine Interne

Volumn 21, Issue 5, 2000, Pages 435-438

  Maloisel, F ^a   Andres E ^a   Campos, F ^a   Oprea C ^a   Deslandres, M ^a   Randriamahazaka, R ^a   Kurtz, J E ^a   Koumarianou, A ^a   Dufour, P ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Castleman's disease; Immunotherapy; Interferon alpha; Interleukin 6

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; INTERLEUKIN 6;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; DISEASE COURSE; HUMAN; HUMAN HERPESVIRUS 8; MALE; PROGNOSIS; REMISSION;

EID: 0034026704     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)88954-7     Document Type: Article

References (20)

1. Larroche C, Cacoub P, Godeau P. La maladie de Castleman. Rev Med Interne 1996 ; 17 : 1003-13.
2. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 1988 ; 5 : 346-364.
3. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993 ; 20 : 636-47.
4. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized an multicentric Castleman's disease. Ann Intern Med 1998 ; 128 : 657-62.
5. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Miyazaki J, et al. IgG1 plasmocytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 1989 ; 86 : 7547-51.
6. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukine 6 (IL-6/BSF-2) in Castleman's disease. Blood 1989 ; 74 : 1360-7.
7. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman's disease. Blood 1991 ; 78 : 2923-30.
8. Pavlidis NA, Briassoulis E, Klouvas G, Bai M. Is interferon-a an active agent in Castleman's disease. Ann Oncol 1992 ; 3 : 85-6.
9. Tamayo M, Gonzalez C, Majado MJ, Candel R, Ramos J. Long-term complete remission after interferon treatment in a case of multicentric Castleman's disease. Am J Hematol 1995 ; 49 : 259-360.
10. Hsu SM, Waldron JA, Xie SS, Barlogie B. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993 ; 24 : 833-9.
11. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated Herpesvirus-like DNA sequences in mulcentric Castleman's disease? Blood 1995 ; 86 : 1271-80.
12. Beck JT, Hsu SM, Widjenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994 ; 330 : 602-5.
13. Van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994 ; 84 : 1434-41.
14. Ogata A, Nishiro N, Shima Y, Yoshizaki K, Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994 ; 84 : 3040-6.
15. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995 ; 85 : 863-72.
16. Gutterman JU. The role of interferons in the treatement of hematologie malignancies. Semin Hematol 1988 ; 25 : 3-8.
17. Boulanger E. L'herpès virus humain 8 (HHV8). II. Rôle pathogène et sensibilité aux antiviraux. Ann Biol Clin 1999 ; 57 : 19-28.
18. Maloisel F, Voillat L, Chenard MP, Boehn A, Lioure B, Dufour P. Interferon-α-2b in the management of patients with relapsed and/or refractory Hodgkin's disease. Ann Oncol 1997 ; 8 : 405-6.
19. Maloisel F, Uettwiller F, Laplace A, Lioure B, Herbrecht R, Mark E, et al. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet 1999 : 1-5.
20. Peschel C, Aman MJ, Rudolf G, Aulitzky WE, Huber C. Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. Semin Hematol 1993 ; 30 Suppl 3 : 28-31.